Who is sponsoring NCT04799314?

NCT04799314 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT04799314?

Interventions in NCT04799314: PD-1 Inhibitor Tislelizumab maintenance therapy.

What condition does NCT04799314 study?

NCT04799314 studies Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy.

Is NCT04799314 still recruiting?

NCT04799314 is currently status unknown. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT04799314

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Status unknown Phase 3 Last updated 16 March 2021

What this trial tests

Phase 3 trial testing PD-1 Inhibitor Tislelizumab maintenance therapy in Lymphoma, Large B-Cell, Diffuse in 132 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
1 April 2023

1 April 2024

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	132
Start date	1 April 2021
Primary completion	1 April 2023
Estimated completion	1 April 2024
Sites	1 location across China

Drugs / interventions tested

PD-1 Inhibitor Tislelizumab maintenance therapy — full drug profile →

Conditions studied

Lymphoma, Large B-Cell, Diffuse — all drugs for Lymphoma, Large B-Cell, Diffuse →
Transplantation — all drugs for Transplantation →
Chemotherapy — all drugs for Chemotherapy →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 65, any sex, with Lymphoma, Large B-Cell, Diffuse or Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, randomized controlled, prospective clinical trial. The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients after autologous hematopoietic stem cell transplantation (ASCT).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K, Uhl B, Krstic J, Szmyra M, et al · · 2021 · cited 87× · PMID 34948104 · DOI 10.3390/ijms222413311
Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review.
Perdikis-Prati S, Sheikh S, Bouroumeau A, Lang N. · · 2023 · cited 6× · PMID 37371815 · DOI 10.3390/biomedicines11061720

Verify or expand the search:

Other trials of PD-1 Inhibitor Tislelizumab maintenance therapy

Trials testing the same drug.

NCT04789434 — PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT · Phase 3 · unknown

Other recruiting trials for Lymphoma, Large B-Cell, Diffuse

Currently open trials in the same condition.

NCT06890884 — A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R- · Phase 2 · recruiting
NCT06254495 — A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers · Phase 1 · active not recruiting
NCT06093841 — Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL · Phase 2 · active not recruiting
NCT05800366 — A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
NCT05798156 — Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell · Phase 2 · active not recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04799314 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04799314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing